Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $20.50.
Several brokerages have commented on TARA. HC Wainwright reissued a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 28th. Jones Trading raised Protara Therapeutics to a "strong-buy" rating and set a $21.00 price objective on the stock in a report on Thursday, May 22nd. Lifesci Capital began coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price objective on the stock. Cantor Fitzgerald began coverage on Protara Therapeutics in a report on Friday, March 14th. They issued an "overweight" rating on the stock. Finally, Scotiabank started coverage on Protara Therapeutics in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective on the stock.
Check Out Our Latest Report on Protara Therapeutics
Insiders Place Their Bets
In other Protara Therapeutics news, insider Jacqueline Zummo sold 21,224 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now owns 98,861 shares of the company's stock, valued at approximately $447,840.33. The trade was a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.40% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Protara Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARA. Charles Schwab Investment Management Inc. acquired a new position in shares of Protara Therapeutics in the 1st quarter valued at $64,000. HBK Investments L P purchased a new stake in Protara Therapeutics during the 4th quarter worth about $106,000. Squarepoint Ops LLC purchased a new stake in Protara Therapeutics during the 4th quarter worth about $110,000. Dimensional Fund Advisors LP purchased a new stake in Protara Therapeutics during the 4th quarter worth about $111,000. Finally, American Century Companies Inc. purchased a new position in shares of Protara Therapeutics in the 1st quarter valued at about $154,000. Institutional investors and hedge funds own 38.13% of the company's stock.
Protara Therapeutics Trading Down 3.1%
Shares of TARA traded down $0.10 during midday trading on Thursday, reaching $3.12. 173,095 shares of the stock were exchanged, compared to its average volume of 772,655. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The company's 50 day moving average is $3.60 and its two-hundred day moving average is $4.18. The company has a market capitalization of $120.38 million, a P/E ratio of -1.11 and a beta of 1.34.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.18. On average, sell-side analysts expect that Protara Therapeutics will post -3.32 EPS for the current year.
About Protara Therapeutics
(
Get Free ReportProtara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Recommended Stories

Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.